Region — International. Neutral scientific reference — not offered for sale here.

Set region

Explore Shop Tools Journal Trust

Explore  /  Pramlintide (Symlin)

Research reference — not for sale

Pramlintide (Symlin)

A

lead outcome

Glycemic control — mealtime-insulin adjunct…

grades vary by outcome ↓

Peptide

also called — Pramlintide · trade name Symlin (SymlinPen 60 / 120) · pramlintide acetate. INCI: none

glycaemic (T1D & T2D adjunct)postprandial glucose/glucagon controlmodest weight losssatiety

The original amylin drug — approved for 20 years, and the honest foil to the amylin revival. Three points define this entry: (1) it is the founding amylin analog and a genuinely FDA-approved drug (Symlin, 2005) — real, marketed, on-label; (2) but it is modest and niche — small weight loss, three-times-daily injections, an insulin adjunct, not a standalone obesity drug — which is exactly why it was underused; (3) it is the direct ancestor of the hot amylin class now reshaping obesity (Cagrilintide #5, Petrelintide, Eloralintide, Amycretin #51). It's the "approved but modest" counterweight to those newer stars.

In brief

Pramlintide is the original amylin analog and a long-approved drug (Symlin, FDA 2005) — a synthetic version of amylin, the satiety/glucose hormone co-released with insulin. It works centrally (in the brainstem's area postrema) to suppress post-meal glucagon, slow gastric emptying, and increase satiety, which lowers post-meal glucose spikes and modestly reduces weight. Its honest limits are what define it: HbA1c drops only ~0.3–0.6% and weight loss only ~1–2.3 kg, it must be injected three times daily (at meals, separate from insulin), it's an insulin adjunct (not standalone), it raises hypoglycemia risk when combined with insulin, and nausea is the main side effect. Those limits — modest efficacy, heavy injection burden — are exactly why it was underused and eclipsed by once-weekly GLP-1 drugs. But it proved the amylin concept, and the pathway has now come roaring back through long-acting, once-weekly successors (Cagrilintide, Petrelintide, Eloralintide) and amylin/GLP-1 combos (CagriSema, Amycretin). Pramlintide is the approved-but-modest grandfather of a suddenly-hot class.

Legal standing, by region

International

availability limited

availability limited; primarily a US drug.

Evidence, by outcome

How we grade →

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade

Glycemic control — mealtime-insulin adjunct (T1D & T2D)

Approved and real, but the magnitude is modest; benefit is as an add-on to insulin, not alone; requires 3×/day dosing

Multiple Phase 3 RCTs → FDA approval 2005; HbA1c reduction ~0.3–0.6% on top of insulin

A

Weight (in diabetes / obesity)

Real but small weight effect; never developed/approved as a dedicated obesity drug; dwarfed by GLP-1s and newer amylins

RCTs + meta-analyses: ~1–2.3 kg loss; separate trials in non-diabetic obesity reduced caloric intake per meal

C

Postprandial glucose / glucagon suppression

Well-demonstrated physiologic effect; this is what it does best

Consistent across trials (the core mechanism)

B

Cardiometabolic biomarkers (lipids, BP)

Limited data; secondary effects, not a primary indication

Small studies: modest LDL/triglyceride reductions (T2D/T1D); neutral on blood pressure

C

Safety / tolerability

Nausea most common (dose-escalated, then settles); increased hypoglycemia risk when used with insulin (a boxed concern — insulin dose must be reduced); injection burden (3×/day, separate from insulin) is the practical dealbreaker

Approval-grade dataset

—

Disclosure

Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.

Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.

Evidence changes

Get notified if this changes

We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for Pramlintide (Symlin) changes - nothing else.

Identity

a synthetic 37-amino-acid peptide analog of human amylin (islet amyloid polypeptide, IAPP) — the hormone co-secreted with insulin by pancreatic β-cells after meals. Because native human amylin is highly amyloidogenic (prone to forming toxic fibrils — it's literally the protein in the amyloid deposits of type-2-diabetic islets), pramlintide was engineered by substituting three residues from rat amylin (which doesn't aggregate) while keeping the receptor activity. It carries a disulfide loop (Cys2–Cys7) and an amidated C-terminus.

Mechanism (as proposed)

amylin is co-secreted with insulin after meals; in health the two are complementary partners — insulin drives glucose uptake into tissues, while amylin controls the rate glucose appears in blood. Pramlintide reproduces amylin's three actions, all largely central (via AMY receptors — calcitonin receptor + RAMP subunits — in the hindbrain area postrema): (1) suppresses post-meal glucagon (so the liver dumps less glucose), (2) slows gastric emptying (glucose enters more gradually), and (3) promotes satiety (less food intake). In type 1 diabetes, amylin is absent alongside insulin, which is why replacing it adds control that insulin alone can't provide.

Chemical identifiers

Cross-reference identifiers for the authoritative external databases — not a recipe, and nothing about how to use it.

PubChem CID70691388

InChIKeyTZIRZGBAFTZREM-MKAGXXMWSA-N

SMILESCC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)CNC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CNC=N6)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@@H]8CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N8)[C@@H](C)O)C)[C@@H](C)O)CC(=O)N)NC(=O)[C@H](CCCCN)N

ChEMBLCHEMBL2103758

via PubChem exact-name match (Pramlintide) · high confidence

Sources — 5 cited

01SYMLIN (pramlintide acetate) FDA label; FDA approval 2005 (adjunct to mealtime insulin, T1D/T2D).

02Cooper GJS, et al. Purification and characterization of a peptide from amyloid-rich pancreas of type-2 diabetics (amylin). PNAS. 1987 (discovery).

03Reviews of pramlintide in T1D/T2D — modest HbA1c (~0.3–0.6%) + weight (~1–2.3 kg), nausea, hypoglycemia-with-insulin (Dunican; Domecq meta-analysis).

04Kruse T, et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem. 2021 (notes cagrilintide resembles pramlintide) — the bridge to the modern class.

05Long-acting amylin-related peptides for obesity and T2D. (2026 review) — pramlintide as the first AMYR agonist, second-generation successors.

Updated 2026-07-13 (pramlintide's status is stable/old; the moving part is the successor class — re-check Cagrilintide/Petrelintide/Eloralintide milestones)

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds

Explore by goal

A neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.

Region — International

ExploreRegister The Register — full index Categories Trust & COA How we grade Open data Brands

ShopCosmetic peptides Journal Quizzes

TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.